Vanguard Group
BHVN icon

Vanguard Group’s Biohaven BHVN Stock Holding History

Vanguard Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$49.6M Buy
4,395,946
+1,520,756
+53% +$18.8M ﹤0.01% 2166
2025
Q3 		$43.2M Sell
2,875,190
-6,374,407
-69% -$92.8M ﹤0.01% 2229
2025
Q2 		$131M Buy
9,249,597
+828,805
+10% +$14.8M ﹤0.01% 1715
2025
Q1 		$202M Buy
8,420,792
+6,672
+0.1% +$235K ﹤0.01% 1479
2024
Q4 		$314M Buy
8,414,120
+628,211
+8% +$29.3M 0.01% 1310
2024
Q3 		$389M Buy
7,785,909
+514,063
+7% +$20M 0.01% 1190
2024
Q2 		$252M Buy
7,271,846
+962,993
+15% +$38.1M ﹤0.01% 1365
2024
Q1 		$345M Buy
6,308,853
+4,650,702
+280% +$230M 0.01% 1204
2023
Q4 		$71M Buy
1,658,151
+229,168
+16% +$7.13M ﹤0.01% 2036
2023
Q3 		$37.2M Sell
1,428,983
-90,491
-6% -$1.88M ﹤0.01% 2270
2023
Q2 		$36.3M Buy
1,519,474
+214,842
+16% +$3.7M ﹤0.01% 2333
2023
Q1 		$17.8M Buy
1,304,632
+63,334
+5% +$1.01M ﹤0.01% 2637
2022
Q4 		$17.2M Buy
+1,241,298
New +$17.5M ﹤0.01% 2693

Other funds holding BHVN

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group's BHVN Position: Q4 2025 in Review

Vanguard Group increased its Biohaven (BHVN) stake by 53% in Q4 2025, buying an estimated $18.8M and bringing the position to 4,395,946 shares worth $49.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2166.

Vanguard Group first reported a position in BHVN in Q4 2022 and has held it in 13 quarters since. The position peaked at $389M in Q3 2024. 272 funds tracked by Wall St. Rank hold BHVN as of Q4 2025.

  • Vanguard Group held 4,395,946 shares of Biohaven worth $49.6M as of Q4 2025.
  • Vanguard Group bought 1,520,756 Biohaven shares in Q4 2025, an estimated $18.8M.
  • Biohaven made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2166 holding.
  • Vanguard Group first reported a position in Biohaven in Q4 2022 and has held it in 13 quarters since.
  • Vanguard Group's Biohaven position peaked at $389M in Q3 2024.
  • 272 funds tracked by Wall St. Rank held Biohaven as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.